跳至主要内容
临床试验/ACTRN12613000439741
ACTRN12613000439741尚未招募4 期

A clinical and electrophysiological study of the effects of 4-aminopyridine on upper limb impairment in Multiple Sclerosis

Austin Health0 个研究点目标入组 30 人开始时间: 2013年4月17日最近更新:
适应症

试验速览

阶段
4 期
状态
尚未招募
发起方
Austin Health
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • Patients with multiple sclerosis who are currently taking modified release fampridine 10mg bd and who are willing to stop the drug for at least 10 days in order to permit measurements to be taken and compared on and off drug; preserved cognitive function permitting informed consent for participation.

排除标准

  • The following are contraindications to fampridine therapy: history of seizures or epilepsy; hypersensitivity to fampridine; moderate/severe renal impairment; pregnancy; current or recent (60 days) MS relapse; alternative likely cause for upper limb impairment (e.g. peripheral neuropathy, injury); current or recent (60 days) therapy with corticosteroids; current therapy with benzodiazepines; recent (within 60 days) addition of new therapy for multiple sclerosis including disease-modifying therapies and symptomatic therapies.

研究者

发起方
Austin Health

相似试验